MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the deal’s $900 million upfront payment makes it one of the largest for a European biotech in the past year, MorphoSys shares fell as investors appeared dissatisfied with the company’s partner of choice.

The deal will see MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) co-commercialize the anti-CD19

Read the full 812 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE